Advances in Pulmonary Medicine 2026

Needs Statement

This comprehensive one-day course in advanced pulmonary medicine is designed to meet the evolving educational needs of pulmonologists, advanced practice providers, and primary care physicians. Recognizing the professional practice gaps in current diagnostic and treatment strategies, the curriculum offers a review of interstitial lung disease, COPD, asthma, bronchiectasis, respiratory infections, lung cancer screening, and interventional pulmonary medicine. Participants will gain insights into recent therapeutic advances in ILD, pulmonary hypertension, asthma, and COPD, delivered by renowned experts in the field. The course combines didactic lectures with case-based discussions. A keynote speaker will present a state-of-the-art lecture on recent developments in interpretation of High resolution CT scans of the chest. Through this targeted and interactive format, we aim to bridge knowledge gaps and equip clinicians with the competencies needed for transformative, evidence-based practice.

Educational Objectives

At the conclusion of this activity, the participants should be able to:

• Describe evidence-based management strategies for interstitial lung diseases, including sarcoidosis, idiopathic pulmonary fibrosis, connective tissue disease-related interstitial lung disease, and eosinophilic lung diseases.
• Apply evidence-based strategies for managing uncontrolled asthma, with an emphasis on incorporating biologic therapies into personalized treatment plans.
• Discuss current and emerging treatment strategies for Chronic Obstructive Pulmonary Disease (COPD), including the potential role of biologic therapies.
• Identify key diagnostic and management challenges in patients with non-cystic fibrosis bronchiectasis.
• Describe the diagnostic and evidence-based treatment options for patients with pulmonary hypertension and acute pulmonary thromboembolic disease.
• Identify evidence-based management strategies and review current guidelines for Non-Tuberculous Mycobacterial infections and community-acquired pneumonia.
• Summarize recent advances and best-practice recommendations for diagnosing and treating complex pleural diseases.
• Describe risk-based strategies for lung cancer detection, incorporating phenotypic profiles, CT screening, and best practices for lung nodule evaluation.

Target Audience

Competencies

• Employ Evidence-Based Practice
• Interprofessional Communication
• Medical Knowledge
• Patient Care and Procedural Skills
• Practice-Based Learning and Improvement
• Provide Patient-Centered Care
• Quality Improvement
• Roles/Responsibilities
• Teams and Teamwork

Accreditation/Credit Designation

Physician

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 8.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC CREDIT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 8.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.